The present specification describes a modular, portable hemofiltration system, for providing improved clearance levels of blood toxins, which includes at least one roller pump that is designed and operated to generate a rapidly varying pressure profile of fluid within at least a blood circuit of the hemofiltration system.

The present invention pertains to an extracorporeal blood treatment device (1), preferably a hemodialysis device, hemofiltration device, or hemodiafiltration device, comprising a fluidic system (2) having a connection point (20) for adding substances, a detection arrangement (4) for detecting a flow of a substance at the connection point (20), wherein the detection arrangement is configured to generate a flow signal, when a flow of a substance is detected at the connection point (20), and a control unit (5), which is communicatively connected to the detection arrangement (4). The control unit (5) is furthermore configured to output a signal (50) in reaction to a received flow signal. The present invention furthermore pertains to a corresponding method for monitoring at least one connection point.

A disposable cartridge for use in a hemodialysis machine has a blood flow path for carrying a volume of blood to be treated in a dialyser and a dialysate flow path, isolated from the blood flow path, for delivering a flow of dialysate solution through the dialyser. The cartridge is received in an engine section of the machine. The engine section has first and second platens which close when the cartridge is inserted to retain the cartridge. Actuators and sensors arranged on the second platen control operation of the cartridge.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

The present invention relates to an insert piece for a blood tubing set that includes a first connection site for connecting a first tubing portion of the blood tubing set to the insert piece; a second connection site for connecting a second tubing portion of the blood tubing set to the insert piece; a third connection site for connecting a third tubing portion of the blood tubing set to the insert piece; a first main line for conducting a first liquid through the insert piece; a second main line for conducting the first liquid through the insert piece; a secondary line for conducting a second liquid into at least one of the first main line, and the second main line; and a connection portion which connects both main lines to each other or to the second connection site.

A blood filtration system can reduce the amount of plasma constituents (e.g., water and/or electrolytes) in the blood of the patient, and accordingly increase the hematocrit value of the patient. The blood filtration system (e.g., a controller, or the like) can determine a hematocrit value of a patient. The blood filtration system can determine a venous pressure of vasculature of a patient. The blood filtration system can compensate for pressure head in a component of a blood circuit (e.g., a withdrawal line of a catheter), for example to improve the accuracy of the venous pressure determination. The blood filtration system can determine one or more resistance characteristics of a blood circuit for the blood filtration system. The resistance characteristics can correspond to a resistance to a flow of blood through a component of the blood circuit.

Methods and systems for maintaining patient fluid balance during an extracorporeal cell treatment are disclosed. The method includes minimizing the amount of saline or other fluid that is returned to the donor. Saline used during priming of the fluid circuit may be used to increase the volume of the collected cells to arrive at a treatment-ready product with a suitable hematocrit.

The present disclosure provides, among other things, methods and systems for treating or removing blood clots in a biological fluid. In some embodiments, the present disclosure provides dialysis-like systems for capturing blood clots. The present disclosure encompasses the recognition that such methods and systems are useful for patients at risk for pulmonary embolism (e.g., patients with deep vein thrombosis and/or COVID-19 patients).

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets.

A system for collecting plasma comprises a separator to separate whole blood from a donor into a plasma product and a second blood component, an anticoagulant line to combine anticoagulant with the whole blood, a touchscreen, and a controller. The controller is configured to receive donor parameters electronically from a donor management system. The controller is configured to use a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The controller is configured to control the system to operate draw and return phases to withdraw whole blood from a donor and return the second blood component to the donor until a volume of raw plasma in the collection container equals the target volume of raw plasma.